Reviews Tesa

the board's sources

Tesamorelin References: The Cited Literature

Every quantitative claim on this site maps to one of these sources. Listed with journal, year, DOI, and PubMed or document link.

Back to the trialsCommon questions

How to read this list

This is the full reference list behind the tesamorelin digest. Each inline marker like [1] or [3] on the research, mechanism, dosage, and FAQ pages resolves to the numbered entry here. Sources are primary where possible — peer-reviewed trials and reviews from the New England Journal of Medicine, JAMA, AIDS, the Journal of Clinical Endocrinology and Metabolism, and others — plus the FDA prescribing label and the NIH LiverTox drug-safety monograph. Links point to PubMed, the NCBI Bookshelf, or the FDA document. Where a DOI exists, it is given for permanent resolution.

  1. Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, Berger D, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370. ↗
  2. Falutz J, Allas S, Mamputu JC, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS. 2008;22(14):1719-1728. ↗
  3. Stanley TL, Feldpausch MN, Oh J, Branch KL, Lee H, Torriani M, Grinspoon SK. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380-389. ↗
  4. Stanley TL, Chen CY, Branch KL, Makimura H, Grinspoon SK. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J Clin Endocrinol Metab. 2011;96(1):150-158. ↗
  5. National Institute of Diabetes and Digestive and Kidney Diseases. Tesamorelin. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): NCBI Bookshelf (NIH); 2018. ↗
  6. Spooner LM, Olin JL. Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy. Ann Pharmacother. 2012;46(2):240-247. ↗
  7. Wang Y, Tomlinson B. Tesamorelin, a human growth hormone releasing factor analogue. Expert Opin Investig Drugs. 2009;18(3):303-310. ↗
  8. Falutz J, et al. A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation. AIDS. 2005;19(12):1279-1287. ↗
  9. Dhillon S. Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy. Drugs. 2011;71(8):1071-1091. ↗
  10. Sivakumar T, et al. Growth hormone axis treatments for HIV-associated lipodystrophy: a systematic review of placebo-controlled trials. HIV Med. 2011;12(8):453-462. ↗
  11. Lake JE, La K, Erlandson KM, Adrian S, Yenokyan G, Scherzinger A, Dube MP, Stanley T, Grinspoon S, Falutz J, Mamputu JC, Marsolais C, McComsey GA, Brown TT. Tesamorelin improves fat quality independent of changes in fat quantity. AIDS. 2021;35(9):1395-1402. ↗
  12. Mangili A, Falutz J, Mamputu JC, Stepanians M, Hayward B. Predictors of treatment response to tesamorelin, a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat. PLoS One. 2015;10(10):e0140358. ↗
  13. Rahman F, McLaughlin T, Mesquita P, Morin J, Potvin D, De Chantal M, Aberg JA. Effect of tesamorelin in people with HIV with and without dorsocervical fat: post hoc analysis of phase III double-blind placebo-controlled trial. J Clin Transl Sci. 2023;7(1):e40. ↗
  14. Theratechnologies Inc. Tesamorelin for injection — Full Prescribing Information. U.S. FDA (NDA 022505); 2025. ↗
  15. Badran AS, et al. Body composition, hepatic fat, metabolic, and safety outcomes of tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: a meta-analysis of randomized controlled trials. Obes Res Clin Pract. 2026. ↗
  16. Gonzalez-Sales M, et al. Population pharmacokinetic and pharmacodynamic analysis of tesamorelin (apparent plasma clearance ~1,060 L/h; ~13% increase in absorbed fraction by day 14; sustained downstream IGF-1 elevation supporting once-daily dosing). 2015. ↗